Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer by Jonker, D. et al.
PUBLISHED VERSION  
 
D J Jonker, C S Karapetis, C Harbison, C J O'Callaghan, D Tu, R J Simes, D P Malone, C Langer, N 
Tebbutt, T J Price, J Shapiro, L L Siu, R P W Wong, G Bjarnason, M J Moore, J R Zalcberg and S 
Khambata-Ford 
Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of 
advanced colorectal cancer 
British Journal of Cancer, 2014; 110(3):648-655 
© 2014 Cancer Research UK. All rights reserved. From twelve months after its original publication, this 
work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported 
License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ 





























Epiregulin gene expression as a biomarker
of benefit from cetuximab in the treatment
of advanced colorectal cancer
D J Jonker*,1,14, C S Karapetis2,14, C Harbison3, C J O’Callaghan4, D Tu4, R J Simes5, D P Malone3, C Langer6,
N Tebbutt7, T J Price8, J Shapiro9, L L Siu10, R P W Wong11, G Bjarnason12, M J Moore10, J R Zalcberg13 and
S Khambata-Ford3
1The Ottawa Hospital Research Institute, University of Ottawa, 501 Smyth Road, Ottawa, ON K1H 8L6, Canada; 2Flinders Medical
Centre and Flinders University, Flinders Drive, Bedford Park, Adelaide, SA 5042, Australia; 3Research and Development, Bristol-
Myers Squibb, 100 Nassau Park Boulevard, Princeton, NJ 08540, USA; 4NCIC – Clinical Trials Group, Queens University, Cancer
Research Institute, 10 Stuart Street, Kingston, ON K7P 3E3, Canada; 5National Health and Medical Research Council Clinical Trials
Centre, University of Sydney, ABN 15 211 513 464, Camperdown, NSW 1450, Australia; 6Genetech Inc., 1 Dna Way, South San
Francisco, CA 94080, USA; 7Austin Health and University of Melbourne, 145 Studley Road, Heidelberg, VIC 3084, Australia;
8The Queen Elizabeth Hospital and University of Adelaide, 28 Woodville Road, Woodville South SA 5011, Australia; 9Cabrini
Hospital and Monash University, Isabella Street, Malvern, VIC 3144, Australia; 10Princess Margaret Hospital and University of
Toronto, 610 University Avenue, Suite 5-718, Toronto, ON M5G 2M9, Canada; 11Cancercare Manitoba, St Boniface General
Hospital, 409 Tache Avenue, Rm L1-102, Winnipeg, MB R2H 2A6, Canada; 12Sunnybrook Health Sciences Centre, University of
Toronto, 2075 Bayview Avenue, Toronto, ON M4N 3M5, Canada and 13Peter MacCallum Cancer Centre, Australasian
Gastrointestinal Trials Group, University of Melbourne, 1 Street Andrews Place, East Melbourne, VIC 3002, Australia
Background: Anti-EGFR antibody, cetuximab, improves overall survival (OS) in K-ras wild-type chemotherapy–refractory colorectal
cancer. Epidermal growth factor receptor ligand epiregulin (EREG) gene expression may further predict cetuximab benefit.
Methods: Tumour samples from a phase III clinical trial of cetuximab plus best supportive care (BSC) vs BSC alone (CO.17) were
analysed for EREG mRNA gene expression. Predictive effects of high vs low EREG on OS and progression-free survival (PFS)
were examined for treatment–biomarker interaction.
Results: Both EREG and K-ras status were ascertained in 385 (193 cetuximab, 192 BSC) tumour samples. Within the high EREG and
K-ras wild-type status (‘co-biomarker’)-positive group (n¼ 139, 36%), median PFS was 5.4 vs 1.9 months (hazard ratio (HR) 0.31;
Po0.0001), and median OS was 9.8 vs 5.1 months (HR 0.43; Po0.001) for cetuximab vs BSC, respectively. In the rest (n¼ 246, 64%),
PFS (HR 0.82; P¼ 0.12) and OS (HR 0.90; P¼ 0.45) were not significantly different. Test for treatment interaction showed a larger
cetuximab effect on OS (HR 0.52; P¼ 0.007) and PFS (HR 0.49; P¼ 0.001) in the co-biomarker-positive group.
Conclusion: In pre-treated K-ras wild-type status colorectal cancer, patients with high EREG gene expression appear
to benefit more from cetuximab therapy compared with low expression. Epiregulin as a selective biomarker requires further
evaluation.
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Cetuximab, an IgG1 monoclonal antibody targeting the epidermal
growth factor receptor (EGFR), is approved for the treatment of
colorectal cancer. As demonstrated in CO.17, a randomised trial of
the NCIC Clinical Trials Group (NCIC CTG) and the Australasian
Gastro-Intestinal Trials Group (AGITG), cetuximabþ best
supportive care (BSC) improves overall survival (OS) and
progression-free survival (PFS), and better preserves quality of life
for advanced chemotherapy–refractory colorectal cancer compared
with BSC alone (Au et al, 2009; Jonker et al, 2007). Benefit was
limited to patients whose tumours express the wild-type K-ras gene
(Karapetis et al, 2008). However, cetuximab resistance remains
common, with 35% of patients progressing at the first disease
response assessment (Karapetis et al, 2008). Further predictive
biomarkers are needed to improve therapeutic index and cost
effectiveness, and to determine resistance pathways to aid in future
drug development.
Epiregulin (EREG), a ligand for EGFR, is a putative biomarker for
benefit from cetuximab through gene expression profiling
(Khambata-Ford et al, 2007; Baker et al, 2011). In cetuximab-treated
patients, high tumour EREG mRNA expression was associated with
better disease control and PFS (Khambata-Ford et al, 2007).
Epiregulin may stimulate EGFR through an autocrine loop with
positive feedback, and elevated EREG may indicate tumour
dependence on the EGFR pathway. Whether EREG is merely
prognostic or is a true biomarker of benefit from cetuximab requires
a randomised trial with a comparator not exposed to cetuximab.
We undertook a correlative analysis of CO.17 trial patients to
determine whether tumour EREG expression is predictive of
benefit from cetuximab therapy beyond K-ras status. We also
assessed the prognostic implications of EREG expression within the
patients receiving BSC.
MATERIALS AND METHODS
This correlative study was designed by a committee including
members of the NCIC CTG and AGITG. The relevant institutional
review boards approved the study protocol. This included approval
for research involving archived tumour tissue, in accordance with
patient consent.
Patients and trial design. The CO.17 trial design and eligibility
criteria were reported previously (Jonker et al, 2007). The primary
end point of the phase III study was to determine the effect of
cetuximab on OS in patients with anti-EGFR therapy-naive advanced
colorectal cancer who had failed all chemotherapy and for whom no
standard anticancer therapy was available. Patients were randomised
to receive cetuximabþBSC or BSC alone. Cetuximab was adminis-
tered as an intravenous loading dose of 400mgm2 over 120min
on day 1, followed by a maintenance schedule of 250mgm2
intravenously over 60min once a week until disease progression or
intolerable toxicity. Eligible patients were enrolled between December
2003 and August 2005. Patients in both arms were evaluated for
tumour response or progression every 8 weeks.
Tumour collection and processing. Formalin-fixed, paraffin-
embedded tumour tissue samples from archival (e.g. diagnostic
or prior colectomy) specimens were banked at Queen’s University
in Kingston, Ontario, Canada. Tissue samples were assayed for
EREG mRNA expression in a blinded manner by the Department
of Clinical Biomarkers-Oncology at Bristol-Myers Squibb,
Hopewell, NJ, USA.
Epiregulin expression analysis. Blinded to clinical outcome, EREG
expression analysis was performed using quantitative real-time PCR
followed by extracting total RNA from formalin-fixed, paraffin-
embedded tissue slides or sections (RNeasy FFPE kit; Qiagen, Venlo,
The Netherlands). Epiregulin gene expression levels were detected by
quantitative real-time PCR. Total RNA was isolated from whole
FFPE tissue sections using the RNeasy FFPE kit (Qiagen). Quality
and quantity of RNA were measured using the NanoDrop spectro-
photometer (Thermo Scientific, Waltham, MA, USA), and 1mg of
RNA was converted to cDNA using the High-Capacity cDNA
Reverse Transcription kit (Applied Biosystems). Polymerase chain
reactions were performed using 140ng cDNA and Assay on Demand
primer/probe reagents from Applied Biosystems (GAPDH:
Hs00266705_g1; EREG: Hs00154995_m1). Using the delta cycle
threshold (DCt) method, which measures the difference between the
cycle time of the biomarker and that of a reference gene, a
normalised DCt value for EREG expression relative to GAPDH
expression was determined for each sample. A smaller normalised
DCt for the biomarker corresponds to higher gene expression.
Statistical analysis. Statistical analyses were performed at the
NCIC CTG in accordance with a prespecified statistical analysis
protocol. The co-biomarker analysis was undertaken after a
preliminary analysis of EREG alone. All randomised subjects
who had both K-ras mutation and EREG expression data available
were included in the analyses, representing the EREG evaluable
data set. The primary end point, OS, was defined as the time from
randomisation until death from any cause. The secondary end
points were PFS, defined as the time from randomisation until the
first objective observation of disease progression or death from any
cause, and response rates, defined by the RECIST criteria.
Epiregulin expression, as a continuous variable, was assessed using
both a prespecified threshold (DCt¼ 6.27) derived from a prior
study (Khambata-Ford et al, 2007), as well as a more exploratory
analysis using a threshold that had a minimum P-value, among all
potential thresholds, for the interaction term in a Cox model for
OS, which included treatment, EREG expression dichotomised at
the threshold and their interaction as covariates, without adjust-
ment for multiple comparisons. The survival of subjects by K-ras
mutation status, EREG expression and/or treatment group was
summarised using Kaplan–Meier curves and differences compared
by log-rank test with the hazard ratio (HR) and its 95% confidence
interval (CI) calculated based on the Cox regression model with a
single covariate. A ‘co-biomarker’-positive group predicted to have
greatest benefit from cetuximab therapy was defined as those
patients with both K-ras wild-type status and high EREG
expression, using each threshold. A Cox regression model with
‘co-biomarker’ status, treatment and ‘co-biomarker’ status by
treatment interaction as covariates was studied. To assess the
independent prognostic effects of EREG expression, a multivariate
Cox regression model was fitted to only BSC patients, including the
following protocol-specified covariates: ECOG performance status
(0–1 vs 2), gender (male vs female), age (X65 vs o65 years),
baseline lactate dehydrogenase level (4UNL vs pUNL), baseline
alkaline phosphatase (4UNL vs pUNL), baseline haemoglobin
(oLLN vs XLLN), number of disease sites (42 vs p2), number
of previous chemotherapy drug classes (42 vs p2), primary
tumour site (rectum only vs colon) and presence of liver metastases
(yes vs no). We used the Cox model with treatment, K-ras
mutation status, EREG expression and their interaction as
covariates to assess the interaction between treatment and
biomarker status, with the primary analysis being among patients
with K-ras wild-type status. This interaction test assesses whether
the treatment effect was significantly different for patients with
different biomarker status. All reported P-values were two-sided
and not adjusted for multiple testing.
RESULTS
Characteristics of the patients. Five hundred and seventy-two
patients were randomly assigned to receive cetuximab (287) or
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BSC (285). A total of 385 tumour specimens (193 cetuximab arm;
192 BSC arm) were evaluable for both K-ras mutation status and
EREG expression, representing 67% of the total study population.
Tumour specimens from the remaining patients were not
retrievable for this analysis for reasons including lack of consent
for tissue research, insufficient tissue and refusal or inability of the
laboratory of origin to release tissue for research. Of these 385
EREG evaluable tumours, 42% had detectable K-ras mutations.
The distribution of low vs high EREG varied depending on the
threshold selected as summarised in Table 1 and Supplementary
Figure A. The prespecified normalised cycle time value was 6.27.
The minimum P-value threshold identified a cycle time of 7.21,
defining fewer K-ras wild-type patients as low EREG expression
and then the prespecified threshold (56 vs 86 patients).
Co-biomarker positivity (K-ras wild-type/high EREG) was found
in 139 (36.1%) and 169 (43.9%) of EREG evaluable patients using
the prespecified and minimum P-value thresholds, respectively.
The baseline demographic and disease characteristics of patients
in the total study population and the EREG evaluable data set are
summarised in Table 2. The EREG low and high groups defined by
the minimum P-value threshold were similar with respect to these
baseline characteristics including ECOG performance status and
other variables found to be associated with survival in the
multivariate analysis. The distribution of each of these character-
istics in the EREG evaluated data set was also similar to that
observed in the total study population. Non-protocol crossover to
cetuximab treatment occurred in 13 BSC patients (four before and
nine after progression).
EREG as a continuous variable. The median EREG normalised
DCt was 5.56 (range 0.79–11.89). As a continuous variable and
adjusted for prognostic factors, lower EREG expression (higher
normalised DCt) was associated with worse OS in both BSC (HR
1.17; 95% CI: 1.04–1.32; P¼ 0.01) and cetuximab-treated patients
(HR 1.13; 95% CI: 1.01–1.27; P¼ 0.04) in the K-ras wild-type
subset. Lower EREG expression was also associated with worse PFS
in the cetuximab-treated patients (HR 1.13; 95% CI: 1.01–1.26;
P¼ 0.03), but not in the BSC arm (P¼ 0.48). As a biomarker for
benefit from cetuximab therapy in K-ras wild-type patients, EREG
as a continuous variable did not achieve statistical significance for
OS (P¼ 0.30) or PFS (P¼ 0.08) with interaction testing.
Overall survival. In the co-biomarker-positive group (K-ras wild-
type/EREG high), the median OS was 9.8 months for cetuximab vs
5.1 months for BSC (HR 0.43; 95% CI: 0.29–0.64; Po0.001) when
defined by the prespecified EREG threshold. Using the minimum
P-value threshold, the median OS was 9.9 months for cetuximab vs
5.0 months for BSC (HR 0.46; 95% CI: 0.32–0.65; Po0.001)
(Figure 1A). In the co-biomarker-negative group (K-ras mutant or
EREG low), OS was not significantly improved with the addition of
cetuximab therapy, whether the EREG expression was dichot-
omised by the prespecified threshold (HR 0.90; 95% CI: 0.68–1.19;
P¼ 0.45) or the minimum P-value threshold (HR 0.97; 95%
CI: 0.72–1.30; P¼ 0.82). In the subset with both K-ras wild-type
and low EREG expression (Figure 1B), cetuximab therapy was not
associated with an improvement in OS (HR 0.93; 95% CI:
0.51–1.71; P¼ 0.81), with a median of 6.51 vs 4.80 months and a
1-year OS of 20.7% vs 24.5% in the cetuximab vs BSC arms,
respectively. Among patients with K-ras wild-type tumours,
interaction testing was nonsignificant for treatment effect by
EREG status on OS (HR 0.62; 95% CI: 0.33–1.15; P¼ 0.13) using
the prespecified threshold or using the minimum P-value threshold
(HR 0.54; 95% CI: 0.27–1.08; P¼ 0.08). Among all patients, co-
biomarker positivity was a significant predictor for OS benefit from
cetuximab therapy using either the prespecified threshold (HR
0.53; 95% CI: 0.32–0.87; P¼ 0.01) or the minimum P-value
threshold (HR 0.45; 95% CI: 0.28–0.73; P¼ 0.001. Figure 2
illustrates a Forest plot for OS by treatment arm and subgroup
using the minimum P-value method (adjusted analysis). Epiregulin
expression was found to be correlated with OS benefit from
cetuximab in K-ras wild-type but not mutant status patients
(adjusted HR 0.45; 95% CI: 0.21–0.97 vs 1.03, 95% CI: 0.48–2.22).
Progression-free survival. In the co-biomarker-positive group (K-
ras wild-type and EREG high), the median PFS was 5.4 months for
cetuximab vs 1.9 months for BSC (HR 0.31; 95% CI: 0.29–0.64;
Po0.0001) when defined by the prespecified EREG threshold.
Using the minimum P-value threshold, the median PFS was
5.1 months for cetuximab vs 1.9 months for BSC (HR 0.33;














EREG evaluable (N=385) 114 79 111 81
EREG expression Higha Low High Low Higha Low High Low
Pre-specified threshold 66 48 33 46 73 38 38 43
Minimum P-value threshold 84 30 47 32 85 26 50 31
Abbreviation: EREG¼epiregulin.
aThose with both wild-type K-ras status and high EREG were defined as the ‘co-biomarker’-positive group.
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95% CI: 0.22–0.46; Po0.0001). In the K-ras wild-type subset with
low EREG expression, cetuximab was associated with an improve-
ment in PFS using the prespecified threshold (HR 0.61; 95% CI:
0.38–0.98; P¼ 0.035) with a median of 1.9 months in both arms,
but not when the minimum P-value threshold was used (HR 0.70;
95% CI: 0.39–1.24; P¼ 0.21), with a median of 1.8 months both
with and without cetuximab. Interaction testing after adjustment
for covariates demonstrated that in K-ras wild-type patients, high
EREG expression does not significantly predict for PFS benefit
from cetuximab therapy using neither the prespecified (HR 0.70;
95% CI: 0.38–1.27; P¼ 0.24) threshold nor the minimum P-value
threshold (HR 0.54; 95% CI: 0.28–1.06; P¼ 0.074. Figure 2
illustrates a Forest plot for PFS by treatment arm and subgroup.
In K-ras mutant patients, EREG expression was not found to be
correlated with PFS benefit from cetuximab (adjusted HR 0.91;
95% CI: 0.45–1.83; P¼ 0.79).
Response to treatment. There were no objective tumour
responses in patients treated with BSC. Among K-ras mutant
patients, there was one response documented among 33 patients










Age, median (range) (in years) 63.2 (28.6–88.1) 63.3 (28.6–88.1) 63.4 (28.6–88.1) 62.8 (30.8–85.9) 0.68
o65 years, no. (%) 335 (58.6) 31 (58.6) 152 (56.3) 79 (63.7)
X65 years, no. (%) 237 (41.4) 163 (41.4) 118 (43.7) 45 (36.3)
Sex, no. (%) 0.24
Female 204 (35.7) 133 (33.8) 86 (31.9) 47 (37.9)
Male 368 (64.3) 261 (66.2) 184 (68.1) 77 (62.1)
ECOG performance status, no. (%) 0.48
0 136 (23.8) 90 (22.8) 64 (23.7) 26 (21.0)
1 302 (52.8) 224 (56.9) 148 (54.8) 76 (61.3)
2 134 (23.4) 80 (20.3) 58 (21.5) 22 (17.7)
Site of primary cancer, no. (%) 0.87
Colon only 332 (58.0) 245 (62.2) 170 (63.0) 75 (60.5)
Rectum only 133 (23.3) 84 (21.3) 57 (21.1) 27 (21.8)
Colon and rectum 107 (18.7) 65 (16.5) 43 (15.9) 22 (17.7)
Any prior radiotherapy, no. (%) 202 (35.3) 127 (32.2) 82 (30.4) 45 (36.3) 0.24
Prior chemotherapy, no. (%)
Adjuvant therapy 211 (36.9) 142 (36.0) 99 (36.7) 43 (34.7) 0.70
No. of regimens 0.79
1–2 104 (18.2) 74 (18.8) 49 (18.1) 25 (20.2)
3 217 (37.9) 157 (39.8) 106 (39.3) 51 (41.1)
4 159 (27.8) 109 (27.7) 75 (27.8) 32 (27.4)
X5 92 (16.1) 54 (13.7) 40 (14.8) 14 (11.3)
Thymidylate synthase inhibitor 572 (100.0) 394 (100) 270 (100) 124 (100) NA
Irinotecan 550 (96.2) 379 (96.2) 259 (95.9) 120 (96.8) 0.68
Oxaliplatin 559 (97.7) 385 (97.7) 263 (97.4) 122 (98.4) 0.55
Sites of disease, no. (%)
Liver 463 (80.9) 313 (79.4) 220 (81.5) 93 (75.0) 0.14
Lung 368 (64.3) 243 (61.7) 164 (60.7) 79 (63.7) 0.57
Nodes 247 (43.2) 167 (42.4) 115 (42.6) 52 (41.9) 0.90
Ascites 86 (15.0) 61 (15.5) 41 (15.2) 20 (16.1) 0.81
Number of sites of disease, no. (%) 0.18
1 93 (16.3) 68 (17.3) 44 (16.3) 24 (19.4)
2 153 (26.7) 107 (27.2) 79 (29.3) 28 (22.6)
3 173 (30.2) 118 (29.9) 85 (31.5) 33 (26.6)
X4 153 (26.7) 101 (25.6) 62 (23.0) 39 (31.5)
K-ras status, no. (% of evaluable) 0.004
Wild-type 230 (58.4) 225 (58.4) 169 (63.5) 56 (47.1)
Mutant 164 (41.6) 160 (41.6) 97 (36.5) 63 (52.9)
Treatment, no. (%) 0.62
CetuximabþBSC 287 (50.2) 196 (49.7) 132 (48.9) 64 (51.6)
BSC only 285 (49.8) 198 (50.3) 138 (51.1) 60 (48.4)
Abbreviations: BSC¼best supportive care; ECOG¼Eastern Cooperative Oncology Group; EREG¼ epiregulin.
aAlthough 394 patients were EREG evaluable, there were 9 for whom K-ras status was not available, leaving 385 for the combined analysis.
bBetween high and low EREG using w2 for categorical variables and t-test for continuous variables.
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with high EREG by the prespecified threshold, but none in the low
EREG group. This patient did not have a G13D mutation (De
Roock et al, 2010). In the K-ras wild-type subset, the response rate
was 16.7% vs 6.3% in patients with high vs low EREG status by the
prespecified threshold, respectively. Using the minimum P-value
threshold, the response rate was 15.5% vs 3.3% in patients
with high vs low EREG status, respectively. When comparing
the response by study arm (cetuximab vs BSC), the rate was
significantly higher with the addition of cetuximab in those with
high EREG (16.7% vs 0%, Po0.0001), but not for those with low
EREG expression (P¼ 0.25).
Effect of EREG in the best supportive care group. In the BSC
arm, EREG expression was not associated with a significant
difference in OS. The OS HR of overexpressed to normal EREG
was 1.14 (95% CI: 0.84–1.55; P¼ 0.41) (Figure 3). The PFS HR of
overexpressed to normal EREG was 0.85 (95% CI: 0.64–1.14;
P¼ 0.28). The difference remains nonsignificant after adjusting
other protocol-specified factors (for OS: adjusted HR 0.82; 95% CI:
0.58–1.15; P¼ 0.24; for PFS: adjusted HR 0.80; 95% CI: 0.59–1.09;
P¼ 0.16).
DISCUSSION
Our findings demonstrate, for the first time, the potential
predictive value (as opposed to simply prognostic value) of tumour
EREG mRNA expression as a biomarker for OS benefit from
cetuximab in patients with pre-treated advanced colorectal cancer.
Cetuximab treatment was associated with a doubling of both the
median OS and PFS in patients with wild-type K-ras tumours that
also had high EREG expression. There was no significant OS
benefit observed from cetuximab treatment in patients with
K-ras wild-type tumours that displayed low EREG expression.
The differences in treatment effect by EREG expression are
suggestive of a different treatment effect but require validation in
independent studies.
Epidermal growth factor receptor pathway ligands EREG and
amphiregulin (AREG) may stimulate EGFR through an autocrine
loop with positive feedback, and elevated EREG may indicate
tumour dependence on the EGFR pathway. The role of EREG and
AREG as predictive biomarkers of benefit from cetuximab therapy
has been evaluated previously. Khambata-Ford et al (2007)
evaluated tumour EREG and AREG mRNA expression from 110
patients with advanced colorectal cancer treated on a single-arm
cetuximab monotherapy. Subsequently, tumour EREG and AREG
mRNA expression were evaluated in 220 patients with
chemotherapy–refractory colorectal cancer treated with cetuximab
plus irinotecan (Jacobs et al, 2009). Another group analysed 226
cetuximab-treated patients in the first- to third-line setting
(Pentheroudakis et al, 2013). A smaller study of 26 K-ras wild-
type status patients suggested high EREG in combination with
other EGFR ligand expression predicted for improved disease
control and PFS (Yoshida et al, 2013). Like our study, these studies
demonstrated that high EREG expression was associated with
higher tumour response rates and better OS and PFS. However, the
absence of a non-treatment control group in both of these studies
did not allow for separation of predictive (treatment-dependent) vs
prognostic (treatment-independent) effects through interaction
testing. In CO.17 only 7% of patients in the BSC control arm
ultimately received anti-EGFR therapy (postprotocol), making it
ideal to differentiate these effects. The consistency of the findings
from the above single-arm studies with our controlled study
strengthens our findings. Clarifying inconsistencies between
studies, such as the finding of an OS predictive effect of EREG in
K-ras mutant status patients (Pentheroudakis et al, 2013), which
was not observed in our study, may require additional studies.
Possible explanations may include the combination with che-
motherapy in many of these patients, thus possibly indicating that
EREG expression may be predictive of chemotherapy benefit.
Amphiregulin expression was also assessed in our study, but no
significant association with survival according to K-ras status was
observed. Epiregulin and AREG are ligands that are coregulated,
bind the same receptor and have genes found on same
chromosomes. As such, similar prognostic or predictive effects
would be expected. Most data show similar results for AREG and
EREG, but usually favouring EREG as being the better predictor.
For example, one study found a prognostic association for EREG
but not for AREG (Kuramochi et al, 2012). Further research
exploring the biological impact of AREG is needed. Other
investigators have focused on the prognostic implications of high
tumour expression of the ligands. One study evaluated tumour
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Figure 1. Kaplan–Meier curves for OS by treatment for patients
with K-ras wild-type status with (A) high EREG and (B) low EREG
expression (using the minimum P-value threshold). Overall survival was
improved with cetuximab in those with high EREG (Po0.0001) but not
those with low EREG expression (P¼ 0.81). The difference in treatment
effect by subgroup was statistically significant (adjusted P-value for
interaction P¼ 0.041). (A) K-ras wild-type and high EREG expression
(‘co-biomarker’-positive). (B) K-ras wild-type and low EREG expression.
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73 patients with colorectal cancer (Li et al, 2010). They reported
90% coexpression of the ligands and concluded that high ligand
expression is a poor prognostic factor, associated with T stage and
distant metastases. Our trial, with its uniform advanced colorectal
cancer population and a BSC-only control arm refutes this finding.
Although a weak prognostic effect was suggested assessing EREG as
a continuous variable (HR 1.17; P¼ 0.01), neither the minimum
P-value nor the prespecified thresholds identified a prognostic
effect, whether by univariate analysis or after controlling for other
prognostic factors. Thus, there appears little prognostic effect, at
least using archival tissue for patients now in a chemotherapy–
refractory setting.
A high degree of concordance between primary and metastatic
paired tumours has been established for K-ras mutation status.
Modest but significant concordance for EREG mRNA was reported
in 120 patients with paired liver metastases and primary tumours
(Rs¼ 0.58, Po0.0001) (Kuramochi et al, 2012). Although EREG
levels in metastasis appear to correlate with outcome (Khambata-
Ford et al, 2007), as do levels in older archival primary samples
(Baker et al, 2011), it is unknown which is superior.
Unlike the dichotomous K-ras status (wild vs mutant), EREG
expression is a continuous variable with arbitrary categorising
thresholds requiring derivation and validation. Several studies have
derived thresholds that could be utilised in prospective validation
studies. Our own efforts to validate a predetermined threshold
suggested a more discriminatory level.
Another limitation of this analysis is that only 67% of the
CO.17 intention-to-treat (ITT) population had the tissue available.
Although a greater proportion would have increased statistical
power and further reduced the chance of bias, the comparison of
EREG-assessed and ITT populations suggest that EREG-assessed











*Co-biomarker positive cohort (both wild-type K-ras and high EREG). **As previously reported (Karapetis et al, 2008)
K-ras wild type
K-ras wild type, EREG high*




K-ras wild type, EREG high* 




Hazard ratio (95% CCI) 
0.77 (0.64–0.92)













Adjusted P value for
interaction (HR)
0.041(adj HR 0.45 (0.21–0.97))
0.93 (adj HR 1.03 (0.48–2.22))
0.074 (adj HR 0.54 (0.28–1.06))




Figure 2. Forest plot demonstrating HRs for death and progression by K-ras and EREG status. For this analysis, EREG was dichotomised using
the minimum P-value threshold. Interaction testing was adjusted for baseline prognostic covariates. The greatest cetuximab treatment effects were
observed in the co-biomarker-positive group (wild-type K-ras and high EREG status).
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Whenever a biomarker clearly identifies subgroups that benefit
more from a treatment, the biomarker will have limited clinical
utility unless it identifies a population that either should or should
not receive treatment. In the context of an established therapy such
as cetuximab when used in a disease with finite effective treatment
options such as colorectal cancer, a decision to forego therapy
requires a high level of assurance that the patient could not have
benefited from treatment. This study evaluated two thresholds for
EREG mRNA expression. We tried to validate a threshold derived
from a previous study and found it has a good discriminatory level.
We also tried to derive a new threshold based on the minimum
P-value approach. The minimum P-value threshold slightly more
successfully demonstrated a K-ras wild-type population who
currently routinely receive cetuximab, but owing to low tumour
EREG expression have no clinically important effect from this
therapy. Although it provided a slightly better discriminatory level,
this needs validation utilising an independent data set.
The low EREG population represented 56 out of 225 (24.9%) of
K-ras wild-type patients in the minimum P-value analysis.
Interaction testing provides evidence that patients with low EREG
benefit less from cetuximab. Specifically, there was no statistically
significant difference in OS (HR 0.93; P¼ 0.81), PFS (HR 0.70;
P¼ 0.21) or response rate (P¼ 0.25) with vs without cetuximab.
Beyond these statistical tests, in the population with K-ras wild-
type but low EREG expression, there appears to be no clinically
relevant absolute difference in median OS (increase of 0.7 months),
1-year OS (increase of 3.8%) or median PFS (increase of 0 months;
Supplementary Figure B), and 97% of this subgroup did not have
an objective response. Furthermore, given the same cost for much
less gain, the cost per life year saved is likely to be very high
(Mittmann et al, 2009). No apparent benefit is therefore observed
in patients with tumours that are either K-ras mutant status or
have low EREG expression (Supplementary Figure C).
Beyond a means of better selecting patients who will derive
greatest benefit from therapy, identification of markers of
resistance provides insight into biology. Exploration of low EREG
tumours may identify means to overcome resistance or identify
signalling pathways that are relevant for this population. Further
evaluation of the interaction between the ligands and other
signalling pathways (e.g. PI3K/PTEN/AKT/mTOR) is warranted.
An analysis including BRAF and these markers is being conducted.
The era of personalised medicine has dawned for colorectal
cancer. Although this is met with excitement, there is also
sober recognition that the days of having a newly discovered
therapy demonstrating broad benefits for a large population
with a particular site of cancer may be behind us. Future
improvements in cancer outcomes while minimising patient
exposure to ineffective therapy will require a shift in oncology
culture toward tumour profiling at diagnosis, with treatments
based on molecular signature.
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